Business Context and Reporting Period
This Form 8-K Current Report was filed by Prothena Corporation plc on July 30, 2025. The filing reports on the execution of new employment agreements with three senior officers of the Company's subsidiary, Prothena Biosciences Inc.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation terms.
- Tran B. Nguyen (Chief Strategy Officer and CFO): Base salary of $603,792; Target bonus of 50% of base salary.
- Brandon S. Smith (Chief Operating Officer): Base salary of $544,201; Target bonus of 50% of base salary.
- Wagner M. Zago, Ph.D. (Chief Scientific Officer): Base salary of $518,000; Target bonus of 40% of base salary.
Material Changes
The filing memorializes the terms of employment for the named officers, confirming that their base salaries and target bonus percentages remain consistent with their current levels. The primary change is the formalization of severance benefits and equity acceleration terms under new written agreements.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, market outlook, or general risk factors. However, it details specific severance contingencies:
- Termination without cause or resignation for good reason: Officers are entitled to 100% of annual base salary, 100% of target bonus, and up to 12 months of health coverage.
- Change in Control: Severance benefits increase to 150% of annual base salary, 150% of target bonus, and up to 18 months of health coverage.
- Equity: Both scenarios trigger acceleration of vesting for equity awards and extension of post-employment exercise periods.
Investor Verification Checklist
- Verify the total potential cash severance liability for each officer under both standard termination and change-in-control scenarios.
- Review the attached Exhibit 10.1 (Form of Employment Agreement) for specific definitions of "good reason" and "change in control."
- Confirm the impact of equity acceleration on the Company's future dilution and compensation expense.
- Check subsequent filings for any changes to the Prothena Biosciences Inc Amended and Restated Severance Plan referenced in the text.